biologic

Dengvaxia

Dengue Tetravalent Vaccine, Live

Loss of exclusivityMay 2031FDA regulatory exclusivity expiry
CompanySanofi Vaccines US Inc.

Drug detail

Brand nameDengvaxia
Active ingredientDengue Tetravalent Vaccine, Live
Strength4.5-6.0 LOG10 CCID50 CCID50: CELL CULTURE INFECTIOUS DOSE 50
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalMay 2019
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Dengvaxia patent cliff — loss of exclusivity May 2031 | CliffBio